翰森制药(03692.HK) 公布,全资附属上海翰森及江苏豪森(许可人)与Merck Sharp & Dohme LLC(默沙东)订立全球独家许可协议。据此,许可人将授予默沙东开发、生产及商业化临床前口服小分子GLP-1受体激动剂HS-10535的全球独家许可。许可人将获得1.12亿美元首付款,并有资格根据该产品开发、注册审批和商业化进展收取最高19亿美元里程碑付款以及基于产品销售的特许权使用费。...
Source Link翰森制药(03692.HK) 公布,全资附属上海翰森及江苏豪森(许可人)与Merck Sharp & Dohme LLC(默沙东)订立全球独家许可协议。据此,许可人将授予默沙东开发、生产及商业化临床前口服小分子GLP-1受体激动剂HS-10535的全球独家许可。许可人将获得1.12亿美元首付款,并有资格根据该产品开发、注册审批和商业化进展收取最高19亿美元里程碑付款以及基于产品销售的特许权使用费。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.